Inferior performance on selected neuropsychological tests in abstinent schizophrenia patients who have used cannabis

Medical Science Monitor

Volumn 18, Issue 9, 2012, Pages

  Krysta, Krzysztof ^a   Krupka Matuszczyk, Irena ^a   Janas Kozik, Małgorzata ^a   Stachowicz, Małgorzata ^a   Szymszal, Jan ^b   Rybakowski, Janusz K ^c  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

^b SILESIAN UNIVERSITY OF TECHNOLOGY   (Poland)

^c POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Cannabisb; Cognitive functions; Psychoactive substance; Schizophrenia

Indexed keywords

AMPHETAMINE; CANNABIS; OPIATE;

ABSTINENCE; ADULT; ARTICLE; CANNABIS ADDICTION; COGNITION; CONTROLLED STUDY; DETOXIFICATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROPSYCHOLOGICAL TEST; PSYCHOLOGIC TEST; SCHIZOPHRENIA; STROOP TEST; SUBSTANCE ABUSE; VERBAL FLUENCY TEST;

EID: 84866067205     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.883355     Document Type: Article

References (31)

1. Cechnicki A, Hanuszkiewicz I, Polczyk R, Bielańska A: Prognostic value of duration of untreated psychosis in long-term outcome of schizophrenia. Med Sci Monit, 2011; 17(5): CR277-83
2. Kovasznay B, Fleischer J, Tanenberg-Karant M et al: Substance use disorder and the early course of illness in schizophrenia and affective psychosis. Schizophr Bull, 1997; 23: 195-201
3. Addington J, Addington D: Substance abuse and cognitive functioning in schizophrenia. J Psychiatry Neurosci, 1997; 22: 99-104
4. Cleghorn JM, Kaplan RD, Szechtman B et al: Substance abuse and schizophrenia: effect on symptoms but not on neurocognitive function. J Clin Psychiatry, 1991; 52: 26-30
5. Nixon SJ, Hallford HG, Tivis RD: Neurocognitive function in alcoholic, schizophrenic, and dually diagnosed patients. Psychiatry Res, 1996; 30: 35-45
6. Pencer A, Addington J: Substance use and cognition in early psychosis. J Psychiatry Neurosci, 2003; 28: 48-54
7. Serper MR, Bergman A, Copersino ML et al: Learning and memory impairment in cocaine-dependent and comorbid schizophrenic patients. Psychiatry Res, 2000; 14: 21-32
8. Serper MR, Chou YCY: Cognitive functioning in schizophrenic patients with comorbid substance use disorder. In: Sharma T, Harvey P, editors. Cognition in schizophrenia. Impairments: Importance and Treatment Strategies. New York: Oxford University Press, 2002; 229-40
9. Sevy S, Burdick KE, Visweswaraiah H et al: Iowa gambling task in schizophrenia: a review and new data in patients with schizophrenia and cooccurring cannabis use disorders. Schizophr Res, 2007; 92: 74-84
10. Carey KB, Carey MP, Simons JS: Correlates of substance use disorder among psychiatric outpatients: focus on cognition, social role functioning, and psychiatric status. J Nerv Ment Dis, 2003; 19: 300-8
11. Joyal CC, Halle P, Lapierre D, Hodgins S: Drug abuse and /or depresndence and better neuropsychological peeformance in patients with schizophrenia. Schizophr Res, 2003; 63: 297-99
12. Potvin S, Briand C, Prouteau A et al: CANTAB explicit memory is less impaired in addicted schizophrenia patients. Brain Cogn, 2005; 59: 38-42
13. Stirling J, Lewis S, Hopkins R, White C: Cannabis use prior to first onset psychosis predict spared neurocognition at 10-year follow-up. Schizophr Res, 2005; 75: 135-37
14. McCleery A, Addington J, Addington D: Substance misuse and cognitive functioning in early psychosis: a 2 year follow up. Schizophr Res, 2006; 88: 187-91
15. Potvin S, Joyal CC, Pelletier J, Stip E: Contradictory cognitive capacities in substance-abusing schizophrenia patients: a meta-analysis. Schizophr Res, 2008; 100: 242-51
16. Barch DM, Carter CS: Amphetamine improves cognitive function in medicated individuals with schizophrenia and in healthy volunteers. Schizophr Res, 2005; 77: 43-58
17. Barnes TR, Mutsatsa SH, Hutton SB et al: Comorbid substance use and age at onset of schizophrenia. Br J Psychiatry, 2006; 188: 237-42
18. Schnell T, Koethe D, Daumann J et al: The role of cannabis in cognitive functioning of patients with schizophrenia. Psychopharmacology (Berl), 2009; 205: 45-52
19. Mata I, Rodriguez-Sanchez JM, Pelayo-Teran JM et al: Cannabis abuse is associated with decision-making impairment among first episode patients with schizophrenia-spectrum psychosis. Psychol Med, 2008; 38: 1257-66
20. Krysta K, Krupka-Matuszczyk I, Klasik A: Impact of drug abuse on cognitive functioning in schizophrenia. Eur Neuropsychopharmacol, 2005; 15(Suppl.3): 579
21. Sierosławski J: Diagnoza potrzeb w zakresie pomocy narkomanom w Poznaniu. Badanie metodami jakościowymi. Alkoholizm i Narkomania, 1999: 2: 209-24 [in Polish]
22. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). Washington, DC: APA; 1994
23. Fayne M: Recognizing dual diagnosis patients in various clinical settings. In: Solomon J, Zimberg S, Shollar E (eds.), Dual Diagnosis, Evaluation, Training, and Program Development. New York: Plenum Press, 1993; 39-53
24. Kay SR, Fiszbein A, Opler LA: The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull, 1987; 13: 261-76
25. Kucharska-Pietura K, Tylec A, Czernikiewicz A, Mortimer A: Attentional and emotional functioning in schizophrenia patients treated with conventional and atypical antipsychotic drugs. Med Sci Monit, 2012; 18(1): CR44-49
26. Gourovitch ML, Goldberg TE, Weiberger DR: Verbal fluency deficits in patients with schizophrenia: semantic fluency is differentially impaired as compared to phonologic fluency. Neuropsychology, 1996; 6: 573-77
27. Borkowska A: Working memory in schizophrenia and bipolar affective illness (in Polish). Wiadomosci Psychiatryczne, 2006; 9: 11-19
28. Yücel M, Bora E, Lubman DI et al: The impact of cannabis use on cognitive functioning in patients with schizophrenia: a meta-analysis of existing findings and new data in a first-episode sample. Schizophr Bull, 2012; 38: 316-30
29. Rabin RA, Zakzanis KK, George TP: The effects of cannabis use on neurocognition in schizophrenia: A meta-analysis Schizophr Res, 2011; 128: 111-16
30. Coulston CM, Perdices M, Tennant CC: The neuropsychology of cannabis and other substance use in schizophrenia: review of the literature and critical evaluation of methodological issues. Aust NZJ Psychiatry, 2007; 41: 869-84
31. Coulston C, Perdices M, Henderson A, Gin SM: Cannabinoids for the treatment of schizophrenia? A balanced neurochemical framework for both adverse and therapeutic effect of cannabis use. Schizophrenia Research and Treatment, 2011; doi: 10.1155/2011/501726